Reduce administrative intervention Drug price reform "ice-breaking" Guangdong first

The Guangdong Provincial Health and Planning Commission issued a notice on the 10th "on soliciting opinions on the amendments to the relevant measures of the drug trading rules of medical institutions in Guangdong Province", proposing to revise the province's basic and non-base drug trading methods, drug procurement and distribution, drug settlement, transaction supervision and management and management of trading institutions. The circular clearly will give full play to the decisive role of the market mechanism in the allocation of drug resources and reduce the interference of administrative power. This is also the future reform direction of the drug price system.
than most drugs, blood products and narcotic drugs are not subject to local tender prices. If the drug price system is adjusted, these two types of enterprises can take the lead in benefiting. For other drugs, industry insiders suggest that the health insurance department is responsible for bidding, under the premise of the total amount of health insurance payments, pharmaceutical companies can be free to price according to market supply and demand. In this way, we can avoid the restrictions of local tender prices, but also to avoid the price of drugs after the liberalization of the surge.price authorities will fade out
according to soliciting opinions, Guangdong intends to adjust the market price data source collection agencies, market price calculation agencies and the highest temporary retail price calculation agencies 3 institutions. At present, all three institutions belong to the price authorities of Guangdong Province. In the future, these three administrative functions will be replaced by provincial health planning committee, provincial drug trading institutions and medical institutions. The result of the adjustment is to prompt the price authorities to fade out of the price-setting system.
Specific amendment rules are: the same drug different manufacturers of the national provincial winning price and Guangdong's current procurement price and other data by the original "provincial price authorities in cooperation with provincial health authorities to collect" revised for "provincial health and family planning departments to collect"; Trading institutions calculate that the provincial development and reform departments in cooperation with the provincial health and family planning departments, provincial human resources and social security departments to review", the highest temporary retail price from the original "provincial price authorities" in accordance with the prescribed rate of the maximum temporary retail price of each transaction price revised to "medical institutions" according to the transaction price of the temporary retail price of the transaction varieties.
Industry insiders believe that the draft dilutes the role of the price department in the price-setting system, the original intention should be to follow the State Council's proposed idea of decentralization, reduce the administrative power of government departments to intervene, play a decisive role in the allocation of drug resources market mechanism.
's changes to the rules for trading in low-priced drugs have also cheered the market. According to the draft opinion, the low-cost drug will be revised from the original "bargaining deal" to "directly hang up the net". That is to say, in the daily average cost standard Western medicine ≤3 yuan, Chinese medicine ≤5 yuan, by the production enterprises independently quoted, trading institutions directly hanging the net, medical institutions choose their own.
understood that the Guangdong Provincial Development and Reform Commission has previously cancelled the provincial and national development and reform commission pricing range of low-cost drugs in the highest retail prices, nearly 7,000 varieties of dosage forms of low-cost drugs have been liberalized prices. In addition, the drug trading cycle from the original monthly bidding to quarterly bidding, no doubt reduced the pressure on enterprises.Health products and narcotic drugs benefit first
After media reports, the NDRC will be the first to liberalize blood products by the end of 2014, the national unified procurement of anti-immunization drugs and contraceptives, a class of psychotic and narcotic drugs and patented drugs four drug prices. In addition, the price of medicines in the medical insurance catalogue shall be changed to the relevant departments to set the standard of payment for medical insurance, and the actual price shall be determined by the market.
" from the investment point of view, this policy for both types of enterprises constitute a significant benefit. The first is the current oversupply of blood products enterprises, followed by narcotic drug enterprises. These two types of enterprises will benefit significantly from the adjustment of the drug price management system. Industry insiders to China Securities News reporter analysis, the NDRC's drug price reform ideas in the liberalization of retail prices. However, prescription drugs are the majority of drugs, prescription drugs to enter the hospital for sale, must first go through the local base drugs and non-base drugs tender. In other words, although the maximum retail price was liberalized, the tender price remained static, which in fact had no effect on the sale price of the drug at the hospital end.
according to the National Development and Reform Commission drug price management regulations, the maximum retail price of drugs is divided into three categories: government pricing, government-directed prices and market-adjusted prices. The pricing power of the retail price of drugs shall be exercised by the state price management department and the provincial price management department respectively, and the pricing catalogue shall be formulated separately. And the local tender price needs the bidding department to set the market price, and then by the pharmaceutical enterprises in this price range to bid, choose the low bid, fierce competition.
" only blood products and narcotic drugs do not need to go through local tenders directly into the hospital for sale. If the state liberalizes the maximum retail price of drugs, these two types of enterprises can freely price according to cost and market supply and demand, and these two types of enterprises will be the first to benefit from the adjustment of the drug price system. The above-mentioned industry insiders said, "Blood products just need the market clear, but the industry's long-term high business climate has not brought high returns to enterprises, products can not rely on supply and demand for market-oriented pricing, so that companies in the industry in the face of a huge market is very passive." Against
background, the valuation of blood products enterprises has been under pressure for a long time, and the dynamic price-earnings ratio of Hualan Biology, Temple of Heaven Biology and Boya Bio has been below 30 times for a long time. At present, the products of domestic blood products enterprises are mainly divided into two categories: one is human haemoglobin and static injection immunoglobulin (static propylene), most enterprises have the ability to produce;
blood products are basically included in the list of base drugs, subject to the highest retail price control. In the past two years, the NDRC has twice raised the maximum retail price of some blood products, 10g/bottle of human haemoglobin from 360 yuan to 378 yuan, a price increase of 5%. However, relative to the collection difficulty and cost of plasma sources, price increases can be described as "rare". Jingpan conventional agent 2.5g / bottle original price of 412 yuan, currently mentioned 561 yuan, a higher price increase.
" plasma collection difficulty and cost increased year by year, most blood products enterprises for the nutrition subsidies of plasma givers between 200 yuan / person to 300 yuan / person, compared to the level of 150 yuan / person before 2010 has significantly improved. Boya Bio executives told China Securities News that despite increasing cost pressures, but the price is dead, the price loosened is expected to improve the level of profits.And the health insurance system is the key
" the relevant departments to liberalize the price of blood products, a class of psychotic drugs, patented drugs and other four drugs, which will have a profound impact on the entire medical market, prompting some structural changes in the pharmaceutical industry. Liao Xinbo, inspector of the Guangdong Provincial Health and Planning Commission, said that although liberalizing drug prices may lead to higher drug prices, but after price liberalization, prices will tend to be reasonable, to ensure the supply of drugs, there will be no shortage of medicines. This is in line with the law of the market practice, can reduce the past through administrative means to drive down drug prices phenomenon, so that drug prices back to the right way.
an official from the Drug Administration Department of the National Health and Planning Commission told China Securities News that the price of the drug looked beautiful, but far less quickly than expected.
the NDRC liberalizes the management of the highest retail price, how to connect with the medical insurance reimbursement system and how to connect with the bidding system of the health sector is a big problem. The officials said it was difficult to pay for health care. The supporting system of free pricing of drugs is the formulation of the price paid for by medical insurance. "There is no problem with liberalizing drug price control, but it is impossible for pharmaceutical companies to sell as much as possible, and how much health insurance will be reimbursed, and the state's finances cannot afford it, which is the difficulty." The official said the drug bidding system will not disappear any time soon.
how to bypass the tender price, so that pharmaceutical companies can really according to market supply and demand free pricing? Liao Xinbo's plan is, "Who pays who bids, since it is medicare, then the health care department is responsible for bidding." Under the premise that the total amount of medical insurance payment is determined, each drug shall be market-oriented. "
" At present, our drug tender is not really the meaning of the market tender. Liao Xinbo said, "If it is a real market tender, it is possible to choose the most suitable drug among the many varieties, that is, the best price/performance ratio in terms of efficacy and price, rather than the cheapest." We are now always emphasizing the price, either a trick to die, or the higher the trick. Mr
, said it was odd that the government did not supply drugs or consume them, and that it was a bit strange that the government was in charge of a unified tender. The government should not bid for drugs as the main body, but should be directly tendered by the medical insurance department, which provides medicines to the insured according to the doctor's prescription. "Tendering by the health-care sector can bypass local tender price restrictions, allow the market to play a pricing role, and avoid a surge in drug prices after drug prices are liberalized." (Pharmaceutical Network)